There are 10 papers on supraventricular arrhythmia in aging research: 1 trial and 9 observational studies in people.
10 papers study it5 more mention it6 findings
3 new papers in 30 daysSee all 15 papers on supraventricular arrhythmia
“SVT and VT profoundly elevated risks for incident heart failure (HR 79.0 and 32.2, p<0.01) and mortality (HR 11.3 and 8.0, p≤0.01).”
- Human trial1
- Humans9
Associations
5Mortality
upin humans2HR 1.23–11.3
2 studies
Mortality
upin humans2HR 1.23–11.3
Supraventricular arrhythmia is associated with mortality in humans (ARVC-associated pathogenic/likely pathogenic variant carriers) (HR 11.3).
HumansARVC-associated pathogenic/likely pathogenic variant carriers
Supraventricular arrhythmia is associated with mortality in humans (Primary care screening population; compared with exclusively normal sinus rhythm) (HR 1.23, 95% CI 1.02–1.49).
HumansPrimary care screening population; compared with exclusively normal sinus rhythm6.5 years maximum follow-upn = 14,403
Incident heart failure
upin humans1
1 study
Incident heart failure
upin humans1
Supraventricular arrhythmia is associated with incident heart failure in humans (ARVC-associated pathogenic/likely pathogenic variant carriers) (HR 79.0).
HumansARVC-associated pathogenic/likely pathogenic variant carriers
Left atrial conduit strain
upin humans1
1 study
Left atrial conduit strain
upin humans1
Left atrial conduit strain predicts supraventricular arrhythmia in T2DM (AUC 0.692).
Humansin T2DM12 monthsn = 57
Type 2 diabetes
upin humans1
1 study
Type 2 diabetes
upin humans1
Type 2 diabetes is linked with a higher risk of supraventricular arrhythmia in humans (35.1% vs. 2.0% (p < 0.001)).
Humans12 monthsn = 107
Clonal hematopoiesis of indeterminate potential
upin humans1HR 1.11
1 study
Clonal hematopoiesis of indeterminate potential
upin humans1HR 1.11
Clonal hematopoiesis of indeterminate potential is linked with a higher risk of supraventricular arrhythmia in humans (HR 1.11 (95% CI 1.04-1.18); large CHIP HR 1.13 (95% CI 1.05-1.22)).
Humansvariant allele fraction ≥2%n = 13,892
Trial sponsors
1 trial50 people